ACTAS UROLOGICAS ESPANOLAS, vol.38, no.8, pp.515-522, 2014 (Peer-Reviewed Journal)
Article / Article
ACTAS UROLOGICAS ESPANOLAS
Science Citation Index Expanded, Scopus
Prostate cancer, Castration resistant, Chemotherapy, Docetaxel, Toxicity, Survival, MITOXANTRONE PLUS PREDNISONE, ELDERLY-PATIENTS, CLINICAL-TRIALS, OLDER, AGE, PARTICIPATION
Introduction: Docetaxel administered every 3-weeks is the standart treatment of castration resistant prostate cancer (CRPC) but it is associated with dose limiting toxicities. We analyzed the efficacy and tolerability of 3- weekly and weekly docetaxel in a Turkish cohort of CRPC patients with a special emphasis on the elderly patients.